• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rephenidate 10 mg
    / Dexcel


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 X 10 mg

    partial basket chart 12920

    Dosage

    The dosage should be individualized according to the patient’s clinical needs and responses. In the treatment of ADHD, an attempt should be made to time administration to coincide with the periods of greatest academic, behavioural, or social stress. The drug  should be started at a low dose, with increments at weekly intervals. Daily doses above 60 mg are not recommended for the treatment of narcolepsy, or for the treatment of ADHD in children. Daily doses above 80 mg are not recommended for the treatment of ADHD in adults. If symptoms do not improve after dose titration over a period of one month, the drug should be discontinued. If symptoms worsen or other adverse effects occur, the dosage should be reduced or, if necessary, the drug discontinued. If the effect of the drug wears off too early in the evening, disturbed behaviour and/or inability to go to sleep may recur. A small evening dose of the drug tablet may help to solve this problem.
    For full details see prescribing information.


    Indications

    Attention Deficit Hyperactivity Disorder (ADHD). Narcolepsy.


    Contra-Indications

    Hypersensitivity to methylphenidate or to any of the excipients. Anxiety, tension. Agitation. Hyperthyroidism. Pre-existing cardiovascular disorders including severe hypertension, angina, arterial occlusive disease; heart failure, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels).
    During treatment with monoamine oxidase (MAO) inhibitors, or within a minimum of 2 weeks of discontinuing those drugs, due to risk of hypertensive crisis. Glaucoma. Phaeochromocytoma. Diagnosis or family history of Tourette’s syndrome.


    Special Precautions

    Please refer to the license holder for further details.


    Manufacturer
    Laboratorios Rubio S.A, Spain
    Licence holder
    CLOSE